Beximco Pharmaceuticals Ltd. reported unaudited earnings results for the second quarter and half year ended December 31, 2016. For the quarter, the company reported net sales revenue of BDT 3,864,993,000, profit from operations of BDT 902,085,000, profit before tax of BDT 754,365,000, profit after tax of BDT 597,991,000 and earnings per share of BDT 1.47 against net sales revenue of BDT 3,330,625,000, profit from operations of BDT 790,899,000, profit before tax of BDT 671,628,000, profit after tax of BDT 524,550,000 and earnings per share of BDT 1.29 a year ago. For the half year, the company reported net sales revenue of BDT 7,630,591,000, profit from operations of BDT 1,765,664,000, profit before tax of BDT 1,464,066,000, profit after tax of BDT 1,112,941,000, earnings per share of BDT 2.74 and net operating cash flow per share of BDT 2.56, net cash generated from operating activities of BDT 1,036,675,000, acquisition of property, plant and equipment of BDT 922,622,000 against net sales revenue of BDT 6,716,329,000, profit from operations of BDT 1,507,179,000, profit before tax of BDT 1,243,560,000, profit after tax of BDT 945,125,000, earnings per share of BDT 2.33 and net operating cash flow per share of BDT 3.28, net cash generated from operating activities of BDT 1,266,526,000, acquisition of property, plant and equipment of BDT 1,411,265,000 a year ago.